617706-15-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-Bromo-2-fluorophenyl)-2,2,2-trifluoroethan-1-one is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(5-Bromo-2-fluorophenyl)-2,2,2-trifluoroethan-1-one is used as a precursor in the production of novel agrochemicals, such as pesticides and herbicides, that can help improve crop protection and yield.
Used in Materials Science:
1-(5-Bromo-2-fluorophenyl)-2,2,2-trifluoroethan-1-one is also utilized in materials science for the development of new materials with specific properties, such as high thermal stability or unique electronic characteristics.
Safety Precautions:
It is important to handle and use 1-(5-Bromo-2-fluorophenyl)-2,2,2-trifluoroethan-1-one with caution, as exposure to this chemical can cause irritation to the skin, eyes, and respiratory system. Proper safety measures should be taken to minimize the risk of adverse effects.

Upstream product

• 383-63-1 ethyl trifluoroacetate, 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 1039827-16-1 1-(5-bromo-2-fluorophenyl)-2,2,2-trifluoroethanol 

Downstream Products

• 57631-11-5 5-bromo-3-(trifluoromethyl)-1H-indazole 
• 1141877-87-3 1-{5-bromo-2-[(4-methoxybenzyl)amino]phenyl}-2,2,2-trifluoroethanone 
• 1599525-27-5 3-(4-Chlorophenoxy)-6-(hydroxy(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)quinoline-2-carbonitrile 
• 1599525-28-6 2-chloro-3-(4-chlorophenoxy)-4-(trifluoromethyl)quinolin-6-yl(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methanol 
• 1599525-29-7 (3-(4-Chlorophenoxy)-2-ethoxy-4-(trifluoromethyl)quinolin-6-yl)(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methanol 
• 1599525-35-5 (3-(4-Chlorophenoxy)-2-(diethylamino)-4-(trifluoromethyl)quinolin-6-yl)(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methanol 
• 1599524-65-8 6-bromo-3-(4-chlorophenoxy)-4-(trifluoromethyl)quinolin-2(1H)-one 
• 1599524-66-9 6-bromo-2-chloro-3-(4-chlorophenoxy)-4-(trifluoromethyl)quinoline 
• 1599524-67-0 6-bromo-3-(4-chlorophenoxy)-N,N-diethyl-4-(trifluoromethyl)quinolin-2-amine 
• 1599524-68-1 6-bromo-3-(4-chlorophenoxy)-2-ethoxy-4-(trifluoromethyl)quinoline 
• 1600566-90-2 C₂₇H₁₈F₆N₄O 
• 1600566-91-3 C₂₇H₁₈F₆N₄O 
• 1600566-79-7 C₂₉H₂₆F₆N₄O₂*C₄H₆O₄ 
• 1600566-77-5 C₂₉H₂₆F₆N₄O₂*C₄H₆O₄ 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS

The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

HETEROARYL LINKED QUINOLINYL MODULATORS OF RORGAMMAT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndr

BENZOXAZINONE DERIVATIVE

[PROBLEMS] To provide a compound useful as an agent for the treatment of circulatory diseases, nervous system diseases, metabolic diseases, reproductive system diseases, and digestive tract diseases. [MEANS FOR SOLVING PROBLEMS] The compound, which is for use as an active ingredient, is represented by the formula (I): [wherein R1 represents optionally halogenated C1-6 alkyl, etc.; R2 represents, e.g., a group represented by the formula (II-1) or (II-4) (wherein W represents C1-6 alkylene, etc. and R represents C1-6 alkyl, etc.); R3 represents hydrogen, C1-6 alkyl, etc.; X represents -O-, -NH-, etc.; and Y1, Y2, Y3, and Y4 each independently represents -CH-, -N-, etc.].

Discovery of novel benzoxazinones as potent and orally active long chain fatty acid elongase 6 inhibitors

A series of benzoxazinones was synthesized and evaluated as novel long chain fatty acid elongase 6 (ELOVL6) inhibitors. Exploration of the SAR of the UHTS lead 1a led to the identification of (S)-1y that possesses a unique chiral quarternary center and a

5-PYRIDINONE SUBSTITUTED INDAZOLES

Various 5-substituted 1-substituted indazoles are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.